Vera Bittner

The University of Alabama

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (12)

Elizabeth Jackson

Professor

The University of Alabama at Birmingham School of Medicine

UNITED STATES

View details

Nicholas Marston

Harvard University

UNITED STATES

View details

Carl Pepine

Professor of Medicine

University of Florida Health Science Center

UNITED STATES

View details

J. Wouter Jukema

Leiden University Medical Center

NETHERLANDS

View details

Deepak Bhatt

Director of Mount Sinai Heart and Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Philippe Gabriel Steg

FRANCE

View details

Lisandro D. Colantonio

UNITED STATES

View details

Timothy Plante

Assistant Professor

Larner College of Medicine, University of Vermont

UNITED STATES

View details

Suzanne Judd

University of Alabama, Tuscaloosa

UNITED STATES

View details

Stephen Clarkson

The University of Alabama

UNITED STATES

View details

Peter Sinnaeve

Professor

University Hospitals Leuven

BELGIUM

View details

Carol Kirkpatrick

University of Idaho

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vera Bittner

Research Interests

Explore related searches

Contact this professor

Articles (20)

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Screening for familial hypercholesterolaemia: children are not small adults

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Familial hypercholesterolaemia: how to further improve outcomes

Body Mass Index, Comorbidities, and Ambulatory Care Visits: The REGARDS Study

Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society

Treatment of heterozygous familial hypercholesterolaemia in children: is lower better?

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests

Long-Term Adverse Outcomes in Black Women With Ischemia and No Obstructive Coronary Artery Disease: A Study of the WISE (Women’s Ischemia Syndrome Evaluation) Cohort

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease

Apolipoprotein B versus non-high-density lipoprotein cholesterol: is the debate really over?

Alirocumab after acute coronary syndrome in patients with a history of heart failure

Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction

An Interprofessional Collaborative Practice Can Reduce Heart Failure Hospital Readmissions and Costs in an Underserved Population

Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction

Collaborators (12)

Elizabeth Jackson

Nicholas Marston

Carl Pepine

J. Wouter Jukema

Deepak Bhatt

Philippe Gabriel Steg

Lisandro D. Colantonio

Timothy Plante

Suzanne Judd

Stephen Clarkson

Peter Sinnaeve

Carol Kirkpatrick

Make your next move.